Mersana Therapeutics Non Current Assets Total Over Time
| MRSN Stock | USD 2.21 0.31 12.30% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Mersana Therapeutics Performance and Mersana Therapeutics Correlation. Mersana |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mersana Therapeutics. If investors know Mersana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mersana Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.85) | Revenue Per Share 0.247 | Quarterly Revenue Growth (0.79) | Return On Assets (0.26) | Return On Equity (2.13) |
The market value of Mersana Therapeutics is measured differently than its book value, which is the value of Mersana that is recorded on the company's balance sheet. Investors also form their own opinion of Mersana Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mersana Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mersana Therapeutics' market value can be influenced by many factors that don't directly affect Mersana Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mersana Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mersana Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mersana Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Non Current Assets Total Analysis
Compare Mersana Therapeutics and related stocks such as Terns Pharmaceuticals, Amylyx Pharmaceuticals, and Acumen Pharmaceuticals Non Current Assets Total Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TERN | 596 K | 596 K | 596 K | 596 K | 596 K | 596 K | 596 K | 596 K | 596 K | 1.7 M | 1.4 M | 1.1 M | 1.8 M | 1.1 M | 1.4 M |
| ABOS | 144 K | 144 K | 144 K | 144 K | 144 K | 144 K | 144 K | 144 K | 144 K | 144 K | 0.0 | 31.7 M | 16.3 M | 63.5 M | 66.7 M |
| INZY | 276 K | 276 K | 276 K | 276 K | 276 K | 276 K | 276 K | 276 K | 276 K | 484 K | 18.4 M | 8.2 M | 7.8 M | 4.6 M | 7.3 M |
| XFOR | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.9 M | 421 K | 924 K | 31.4 M | 39.6 M | 29.3 M | 26.9 M | 25.2 M | 19.2 M |
| DAWN | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 590 K | 453 K | 1.2 M | 774 K | 661.1 K |
| HOOK | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 5.9 M | 15.7 M | 16.3 M | 23.9 M | 23.3 M | 14.2 M | 16.2 M |
| CGEM | 421 K | 421 K | 421 K | 421 K | 421 K | 421 K | 421 K | 421 K | 421 K | 370 K | 2.4 M | 140.6 M | 86.6 M | 4 M | 3.8 M |
| RLAY | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 32.5 M | 29.7 M | 32.2 M | 80.3 M | 73.9 M | 46.4 M |
| RCUS | 10 M | 10 M | 10 M | 10 M | 10 M | 10 M | 10 M | 13.6 M | 16 M | 10.4 M | 37.2 M | 910.6 M | 278 M | 264 M | 211.7 M |
| KURA | 2.5 K | 2.5 K | 2.5 K | 2.5 K | 182 K | 390 K | 1 M | 1.2 M | 1.2 M | 2.4 M | 9.9 M | 11.8 M | 9.9 M | 16.5 M | 17.3 M |
| PTGX | 415 K | 415 K | 415 K | 415 K | 415 K | 639 K | 10.7 M | 12.8 M | 2 M | 9.6 M | 8.9 M | 7 M | 10.6 M | 2.4 M | 2.3 M |
| MRUS | 1.5 M | 1.5 M | 1.5 M | 1.3 M | 1 M | 1.1 M | 1.3 M | 10.4 M | 26.2 M | 16 M | 13.2 M | 32.4 M | 70.1 M | 89.7 M | 94.2 M |
| REPL | 417 K | 417 K | 417 K | 417 K | 417 K | 417 K | 417 K | 448 K | 13.3 M | 59.8 M | 59.4 M | 57.2 M | 54 M | 54.1 M | 41.1 M |
| PLRX | 4.8 M | 4.8 M | 4.8 M | 4.8 M | 4.8 M | 4.8 M | 4.8 M | 4.8 M | 4.8 M | 7.2 M | 4.8 M | 11.8 M | 10.3 M | 6.7 M | 8.3 M |
| SNDX | 775 K | 775 K | 775 K | 2.5 M | 372 K | 1.9 M | 503 K | 3.7 M | 592 K | 1.2 M | 1.7 M | 1.3 M | 16 M | 32 M | 33.6 M |
| RVMD | 5.6 M | 5.6 M | 5.6 M | 5.6 M | 5.6 M | 5.6 M | 5.6 M | 5.6 M | 85.2 M | 86.5 M | 113.3 M | 160.9 M | 151.7 M | 182.4 M | 123.5 M |
| VRDN | 1.1 M | 1.1 M | 1.1 M | 1.6 M | 1.3 M | 1.2 M | 1.2 M | 613 K | 777 K | 523 K | 1.6 M | 3.5 M | 10.5 M | 3.9 M | 2.6 M |
Mersana Therapeutics and related stocks such as Terns Pharmaceuticals, Amylyx Pharmaceuticals, and Acumen Pharmaceuticals Non Current Assets Total description
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.My Equities
My Current Equities and Potential Positions
| Mersana Therapeutics | MRSN |
| Classification | Cancer Fighters |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 2.21
Check out Mersana Therapeutics Performance and Mersana Therapeutics Correlation. To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Mersana Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.